drugset / Trial / NCT06232902
A Study to Compare the Pharmacokinetics and Safety of QL1101 and EU-Avastin® in Healthy Volunteers
RandomizedParallel-groupDouble-blindTreatment
Summary
The goal of this clinical trial is to compare the pharmacokinetic and safety similarity of QL1101 with EU-Avastin® in healthy male volunteers. Participants will receive a single injection of QL1101/ EU-Avastin®.Researchers will compare pharmacokinetic, safety, and immunogenic similarities between the 2 groups.
Timeline
- Start
- 2024-06-20
- Primary completion
- 2024-11-18
- Completion
- 2024-11-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bevacizumab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | QL1101 | Unknown | 3 mg/kg | Intravenous |